ELECTREON
11.4.2022 09:02:16 CEST | Business Wire | Press release
Electreon (TASE: ELWS.TA), the leading provider of wireless and in-road wireless electric vehicle (EV) charging technology, today announced the one year extension of the Smartroad Gotland pilot project in Sweden. The €2 million ($2.17 million) budget for the extension is funded by the Swedish Transport Administration and includes an upgrade of 400 m of the existing installation. Electreon will also extend the run of the electric airport shuttle bus—the shuttle will continue to undergo testing and simultaneously be available for commercial rides, and will open to the public in the summer of 2022. Government stakeholders, commercial fleet operators, and businesses interested in the technology are welcome to visit the project site and learn more about the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005166/en/
“The team at Smartroad Gotland is excited for the one year extension of this project and for the opportunity to demonstrate the continued endurance of our wireless charging technology in Swedish weather,” said Håkan Sundelin, director of the Nordic Region at Electreon and project manager for Smartroad Gotland. “The planned large scale electric road pilot in Sweden, in addition to the French government’s decision to fund pilots for wireless charging roads, shows high demand for Electreon’s technology in Europe.''
Jan Pettersson, program manager of electrification, Swedish Transport Administration said, “We are very positive about the opportunity to test higher wireless charging performance, as well as road durability. Now that the corona restrictions have eased, we are also looking forward to spreading the knowledge from the project more widely.”
As part of the project extension, Electreon will increase the capacity of its receivers to transfer energy to approximately 30 kW and examine a new generation of its technology. This will demonstrate how the wireless charging infrastructure can be upgraded to meet evolving needs over time. Electreon will also deploy its software capabilities, such as its billing feature, which enables the Company to invoice vehicle subscribers using the Electric Road System.
After the upgrade is complete, the long-haul e-truck and commercial passenger e-bus, that have now been utilizing the wireless charging infrastructure for one year as part of this project, will undergo continued testing. The Swedish National Road and Transport Research Institute (VTI) will perform third-party endurance and stress tests to verify that Electreon’s technology and charging coils are unaffected by road construction and heavy-duty truck use. Electreon’s wireless charging technology is designed to be future proof, and this project will continue to prove that Electreon offers long-term performance with minimal maintenance. Additional third-party endurance tests of Electreon’s wireless charging technology are currently being performed as part of the BASt project in Germany and the Arena of the Future project in Italy.
To date, Electreon’s patented technology has been integrated with a wide range of vehicles, as part of its ongoing collaborations with auto manufacturers including Renault, Stellantis, Iveco, and Volkswagen. In February 2022, Electreon announced it was awarded a Michigan Department of Transportation (MDOT) contract for the first public Electric Road System for wireless EV charging in the U.S. In November 2021, Electreon’s wireless charging technology was named one of TIME’s 100 Best Inventions of 2021 .
About Electreon
Electreon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. Electreon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom